<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="monograph-family" /><meta name="keywords" content="Cytokine modulators: rheumatoid arthritis; Adalimumab: rheumatic diseases; Certolizumab pegol; Etanercept: rheumatic diseases; Ankylosing spondylitis; Golimumab; Infliximab: rheumatic diseases; Rituximab: rheumatic diseases; Abatacept; Anakinra; Belimumab; Tocilizumab" /><meta name="IX" content="Cytokine modulators: rheumatoid arthritis; Adalimumab: rheumatic diseases; Certolizumab pegol; Etanercept: rheumatic diseases; Ankylosing spondylitis; Golimumab; Infliximab: rheumatic diseases; Rituximab: rheumatic diseases; Abatacept; Anakinra; Belimumab; Tocilizumab" /><title>Cytokine modulators: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="202659.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="202659.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=202659.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="2077.htm">10 Musculoskeletal and joint diseases</a> &gt; <a href="5182.htm">10.1 Drugs used in rheumatic diseases and gout</a> &gt; <a href="5288.htm">10.1.3 Drugs that suppress the rheumatic disease process</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="5305.htm" title="Previous: METHOTREXATE">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="130136.htm" title="Next: ABATACEPT">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_202659">Cytokine modulators</h1><?highlighter on?><div id="pC" class="jN"><div><p>Cytokine modulators should be used
under specialist supervision.</p><p><span>Adalimumab</span>, certolizumab pegol, <span>etanercept</span>, golimumab, and <span>infliximab</span> inhibit the activity of tumour necrosis factor alpha (TNF-α).</p><div id="_208116"><p><b><span>Adalimumab</span></b> is licensed for moderate to severe active <i>rheumatoid
arthritis</i> when response to other disease-modifying antirheumatic
drugs (including <span>methotrexate</span>) has been inadequate
(see also NICE guidance <a title="BNF:target-block: NICE guidance cytokine modulators and the treatment of rheumatoid arthritis" href="202659.htm#_202818">October 2007</a> and <a title="BNF:target-block: NICE guidance cytokine modulators for treatment of rheumatoid arthritis after TNF failure" href="202659.htm#_213716">August 2010</a>);
it is also licensed for severe, active, and progressive disease in
adults not previously treated with methotrexate. It is also licensed
for active <i>polyarticular juvenile idiopathic arthritis</i> in children who have not responded adequately to one or more disease-modifying
antirheumatic drugs. In the treatment of rheumatoid arthritis and
polyarticular juvenile idiopathic arthritis, adalimumab should be
used in combination with <span>methotrexate</span>, but it can
be given alone if <span>methotrexate</span> is inappropriate.
Adalimumab is also licensed for the treatment of active and progressive <i>psoriatic arthritis</i> (see also <a title="target-block: NICE guidance Etanercept and infliximab for the treatment of psoriatic arthritis" href="202659.htm#_202822">NICE guidance</a>)
and severe active <i>ankylosing spondylitis</i> (see also <a title="BNF:target-block: NICE guidance Cytokine modulators for the treatment of ankylosing spondylitis" href="202659.htm#_202819">NICE guidance</a>)
that have not responded adequately to other disease-modifying antirheumatic
drugs. For the role of adalimumab in Crohn’s disease, see <a title="monograph-family: Cytokine modulators" href="128210.htm#_128210">section 1.5.3</a>. For the role of adalimumab in
plaque psoriasis, see <a title="sub-section: Drugs affecting the immune response" href="106473.htm#_106473">section 13.5.3</a>.</p></div><div id="_204104"><p><b>Certolizumab
pegol</b> is licensed for use in patients with moderate to severe
active <i>rheumatoid arthritis</i> when response to disease-modifying
antirheumatic drugs (including methotrexate) has been inadequate (see
also NICE guidance, below). Certolizumab pegol can be used in combination
with methotrexate, or as a monotherapy if methotrexate is not tolerated
or is contra-indicated.</p><div class="cN"><h2 class="cBR">NICE guidance</h2><h3 class="cBP">Certolizumab pegol for the treatment of rheumatoid
arthritis (February 2010)</h3><p>Certolizumab pegol is an option for the treatment of patients
with rheumatoid arthritis only if:</p><ul class="cBF"><li><p class="cQ">certolizumab pegol is used as described in the NICE guidance
(October 2007)  for other tumour necrosis factor (TNF) inhibitors,
(see <a title="BNF:target-block: NICE guidance cytokine modulators and the treatment of rheumatoid arthritis" href="202659.htm#_202818">Adalimumab, Etanercept and
Infliximab for the treatment of Rheumatoid Arthritis</a>, below) <i>and</i></p></li><li><p class="cQ">the manufacturer provides the first 12 weeks of certolizumab
pegol (10 prefilled 200-mg syringes) free of charge to all patients
starting treatment.</p></li></ul></div></div><div id="_208117"><p><b><span>Etanercept</span></b> is licensed for the
treatment of moderate to severe active <i>rheumatoid arthritis</i> either alone or in combination with <span>methotrexate</span> when the response to other disease-modifying antirheumatic drugs
is inadequate and in severe, active and progressive <i>rheumatoid
arthritis</i> in patients not previously treated with <span>methotrexate</span> (see also NICE guidance <a title="BNF:target-block: NICE guidance cytokine modulators and the treatment of rheumatoid arthritis" href="202659.htm#_202818">October 2007</a> and <a title="BNF:target-block: NICE guidance cytokine modulators for treatment of rheumatoid arthritis after TNF failure" href="202659.htm#_213716">August 2010</a>).
It is also licensed for the treatment of <i>active polyarticular
juvenile idiopathic arthritis</i> in children who have not responded
adequately to or are intolerant of <span>methotrexate</span> (see also <a title="BNF:target-block: NICE guidance Etanercept for the treatment of juvenile idiopathic arthritis" href="202659.htm#_202821">NICE guidance</a>),
active and progressive <i>psoriatic arthritis</i> inadequately
responsive to other disease-modifying antirheumatic drugs (see also <a title="BNF:target-block: NICE guidance Etanercept and infliximab for the treatment of psoriatic arthritis" href="202659.htm#_202822">NICE guidance</a>),
and for severe <i>ankylosing spondylitis</i> inadequately responsive to
conventional therapy (see also <a title="BNF:target-block: NICE guidance Cytokine modulators for the treatment of ankylosing spondylitis" href="202659.htm#_202819">NICE guidance</a>).
For the role of <span>etanercept</span> in plaque psoriasis,
see <a title="sub-section: Drugs affecting the immune response" href="106473.htm#_106473">section 13.5.3</a>.</p></div><div id="_213702"><p><b>Golimumab</b> is licensed
in combination with methotrexate for the treatment of moderate to
severe active <i>rheumatoid arthritis</i> when response
to disease-modifying antirheumatic drug (DMARD) therapy (including
methotrexate) has been inadequate (see also NICE guidance below);
it is also licensed in combination with methotrexate for patients
with severe, active, and progressive rheumatoid arthritis not previously
treated with methotrexate. Golimumab is also licensed for the treatment
of active and progressive <i>psoriatic arthritis</i>, as
monotherapy or in combination with methotrexate, when response to
DMARD therapy has been inadequate (see also NICE guidance below);
it is also licensed for the treatment of severe active <i>ankylosing
spondylitis</i> when there is an inadequate response to conventional
treatment (see also NICE guidance below).</p></div><div class="cN"><h2 class="cBR">NICE guidance</h2><h3 class="cBP">Golimumab for the treatment of rheumatoid arthritis
after the failure of previous disease-modifying antirheumatic drugs
(June 2011)</h3><p>Golimumab, in combination with methotrexate, is an option for
the treatment of rheumatoid arthritis in adults who have had an inadequate
response to conventional disease-modifying antirheumatic drugs (DMARDs)
only, including methotrexate, if:</p><ul class="cBF"><li><p class="cQ">golimumab is used as described in the NICE guidance (October
2007) for other tumour necrosis factor (TNF) inhibitors (see <a title="BNF:target-block: NICE guidance cytokine modulators and the treatment of rheumatoid arthritis" href="202659.htm#_202818">Adalimumab, etanercept, and
infliximab for the treatment of rheumatoid arthritis</a>), <i>and</i></p></li><li><p class="cQ">the manufacturer provides the 100-mg dose of golimumab
at the same price as the 50-mg dose</p></li></ul><p>Alternatively, golimumab, in combination with methotrexate,
is an option for the treatment of rheumatoid arthritis in adults who
have had an inadequate response to DMARDs including a TNF inhibitor,
if:</p><ul class="cBF"><li><p class="cQ">golimumab is used as described in the NICE guidance (August
2010) for other TNF inhibitors (see <a title="BNF:target-block: NICE guidance cytokine modulators for treatment of rheumatoid arthritis after TNF failure" href="202659.htm#_213716">Adalimumab, etanercept, infliximab,
rituximab, and abatacept for the treatment of rheumatoid arthritis
after the failure of a TNF inhibitor</a>), <i>and</i></p></li><li><p class="cQ">the manufacturer provides the 100-mg dose of golimumab
at the same price as the 50-mg dose</p></li></ul></div><div class="cN"><h2 class="cBR">NICE guidance</h2><h3 class="cBP">Golimumab for the treatment of psoriatic arthritis
(April 2011)</h3><p>Golimumab is an option for the treatment of active and progressive
psoriatic arthritis in adults only if:</p><ul class="cBF"><li><p class="cQ">golimumab is used as described in the NICE guidance (August
2010) for other tumour necrosis factor (TNF) inhibitors (see <a title="BNF:target-block: NICE guidance Etanercept and infliximab for the treatment of psoriatic arthritis" href="202659.htm#_202822">Etanercept, infliximab, and
adalimumab for the treatment of psoriatic arthritis</a>), <i>and</i></p></li><li><p class="cQ">the manufacturer provides the 100-mg dose of golimumab
at the same price as the 50-mg dose</p></li></ul></div><div class="cN"><h2 class="cBR">NICE guidance</h2><h3 class="cBP">Golimumab for the treatment of ankylosing spondylitis
(August 2011)</h3><p>Golimumab is an option for the treatment of severe, active ankylosing
spondylitis in adults only if:</p><ul class="cBF"><li><p class="cQ">Golimumab is used as described in the NICE guidance (May
2008) for adalimumab and etanercept (see <a title="BNF:target-block: NICE guidance Cytokine modulators for the treatment of ankylosing spondylitis" href="202659.htm#_202819">Adalimumab, etanercept, and
infliximab for the treatment of ankylosing spondylitis</a>), <i>and</i></p></li><li><p class="cQ">the manufacturer provides the 100-mg dose of golimumab
at the same price as the 50-mg dose</p></li></ul><p>Patients who are already receiving golimumab for the treatment
of severe, active ankylosing spondylitis who do not fulfil the criteria
for treatment with adalimumab and etanercept, described in the NICE
guidance (May 2008), can continue treatment until they and their specialist
consider it appropriate to stop. </p></div><div id="_208118"><p><b><span>Infliximab</span></b> is licensed for the treatment of active <i>rheumatoid arthritis</i> in combination with methotrexate when
the response to other disease-modifying antirheumatic drugs, including
methotrexate, is inadequate (see also NICE guidance <a title="BNF:target-block: NICE guidance cytokine modulators and the treatment of rheumatoid arthritis" href="202659.htm#_202818">October 2007</a> and <a title="BNF:target-block: NICE guidance cytokine modulators for treatment of rheumatoid arthritis after TNF failure" href="202659.htm#_213716">August 2010</a>);
it is also licensed in combination with methotrexate for patients
not previously treated with methotrexate or other DMARDs who have
severe, active, and progressive rheumatoid arthritis. Infliximab is
also licensed for the treatment of <i>ankylosing spondylitis</i>, in patients with severe axial symptoms who have not responded adequately
to conventional therapy (but see also <a title="BNF:target-block: NICE guidance Cytokine modulators for the treatment of ankylosing spondylitis" href="202659.htm#_202819">NICE guidance</a>)
and in combination with <span>methotrexate</span> (or alone
if methotrexate is not tolerated or is contra-indicated) for the treatment
of active and progressive <i>psoriatic arthritis</i> which
has not responded adequately to disease-modifying antirheumatic drugs
(see also <a title="BNF:target-block: NICE guidance Etanercept and infliximab for the treatment of psoriatic arthritis" href="202659.htm#_202822">NICE guidance</a>).</p></div><div id="_208119"><p><b><span>Rituximab</span></b> is licensed in combination
with <span>methotrexate</span> for the treatment of severe active <i>rheumatoid arthritis</i> in patients whose condition has not
responded adequately to other disease-modifying antirheumatic drugs
(including one or more tumour necrosis factor inhibitors) or who are
intolerant of them (see also <a title="BNF:target-block: NICE guidance cytokine modulators for treatment of rheumatoid arthritis after TNF failure" href="202659.htm#_213716">NICE guidance</a>).
For the role of <span>rituximab</span> in malignant disease,
see <a title="BNF:sub-section: Anti-lymphocyte monoclonal antibodies" href="208986.htm#_208986">section 8.2.3</a>.</p></div><div id="_202818"><div class="cN"><h2 class="cBR">NICE guidance</h2><h3 class="cBP">Adalimumab, <span>etanercept</span>, and <span>infliximab</span> for the treatment of rheumatoid arthritis (October
2007)</h3><p>The tumour necrosis factor alpha (TNF-α) inhibitors adalimumab,
etanercept, and infliximab are options for the treatment of adults
with active rheumatoid arthritis who have failed to respond to at
least 2 disease-modifying antirheumatic drugs (DMARDs), including
methotrexate (unless contra-indicated). TNF-α inhibitors should be
given in combination with methotrexate; however, when methotrexate
cannot be used because of intolerance or contra-indications, adalimumab
or etanercept can be given as monotherapy.<br /></p><p>Adalimumab, etanercept, and infliximab should be withdrawn if
response is not adequate within 6 months. Response to treatment should
be monitored at least every 6 months in patients who respond initially;
treatment should be withdrawn if response is not maintained. An alternative
TNF-α inhibitor may be considered for patients in whom treatment is
withdrawn because of intolerance before the initial 6-month assessment
of efficacy.<br /></p><p>Use of TNF-α inhibitors for the treatment of severe, active,
and progressive rheumatoid arthritis in adults not previously treated
with methotrexate or other DMARDs is not recommended.</p></div></div><div id="_213716"><div class="cN"><h2 class="cBR">NICE guidance</h2><h3 class="cBP">Adalimumab, etanercept, infliximab, rituximab, and
abatacept for the treatment of rheumatoid arthritis after the failure
of a TNF inhibitor (August 2010)</h3><p>Rituximab, in combination with methotrexate, is an option for
the treatment of severe active rheumatoid arthritis in adults who
have had an inadequate response to, or are intolerant of, other disease-modifying
antirheumatic drugs (DMARDs), including at least 1 tumour necrosis
factor (TNF) inhibitor. Repeat courses of rituximab should be given
no more frequently than every 6 months, and should only be continued
if an adequate response is achieved and maintained.<br /></p><p>Adalimumab, etanercept, infliximab, or abatacept, in combination
with methotrexate, are options for the treatment of severe active
rheumatoid arthritis in adults who have had an inadequate response
to, or have an intolerance of, other DMARDs including at least 1 TNF
inhibitor, and who cannot use rituximab because of contra-indications
or intolerance. In patients who cannot use methotrexate because of
intolerance or contra-indications, adalimumab or etanercept can be
given as monotherapy. Treatment should be continued only if there
is adequate response. Patients should be monitored at least every
6 months.</p></div></div><div id="_202819"><div class="cN"><h2 class="cBR">NICE guidance</h2><h3 class="cBP">Adalimumab, etanercept, and infliximab for the treatment
of ankylosing spondylitis (May 2008)</h3><p>Adalimumab or etanercept are treatment options for adults with
severe active ankylosing spondylitis whose disease satisfies specific
criteria for diagnosis where there is confirmation of sustained active
spinal disease, and where treatment with two or more NSAIDs taken
sequentially at maximum tolerated or recommended doses for 4 weeks
has failed to control symptoms.</p><p>Response to adalimumab or etanercept treatment should be assessed
at 12-week intervals and continued only if response is adequate. If
response to treatment is not maintained, a repeat assessment should
be made after a further 6 weeks and treatment discontinued if there
is an inadequate response. Patients who are intolerant of adalimumab
or etanercept during the initial 12 weeks may receive the alternative
TNF-α inhibitor (adalimumab or etanercept). However an alternative
TNF-α inhibitor is not recommended in patients who fail to respond
initially or fail to maintain an adequate response.</p><p>Infliximab is not recommended for the treatment of ankylosing
spondylitis. Patients who are already receiving infliximab for the
treatment of ankylosing spondylitis can continue treatment until they
and their specialist consider it appropriate to stop.</p><p>See full NICE guidance for specific criteria to diagnose severe
active ankylosing spondylitis, confirm sustained active spinal disease,
and assess response to treatment.</p></div></div><div id="_202821"><div class="cN"><h2 class="cBR">NICE guidance</h2><h3 class="cBP"><span>Etanercept</span> for the treatment of
juvenile idiopathic arthritis (March 2002)</h3><p><span>Etanercept</span> is recommended in children aged
4–17 years with active polyarticular-course juvenile idiopathic arthritis
who have not responded adequately to <span>methotrexate</span> or who are intolerant of it. <span>Etanercept</span> should
be used under specialist supervision according to the guidelines of
the British Society for Paediatric and Adolescent Rheumatology [previously
the British Paediatric Rheumatology Group].<br /></p><p><span>Etanercept</span> should be withdrawn
if severe side-effects develop or if
there is no response after 6 months or if the initial response is
not maintained. There is no evidence to support treatment for longer
than 2 years; a decision to continue therapy should be based on disease
activity and clinical effectiveness in individual cases.<br /></p><p>Prescribers of <span>etanercept</span> should register
consenting patients with the Biologics Registry of the British Society
for Paediatric and Adolescent Rheumatology.</p></div></div><div id="_202822"><div class="cN"><h2 class="cBR">NICE guidance</h2><h3 class="cBP">Etanercept, infliximab, and adalimumab for the treatment
of psoriatic arthritis (August 2010)</h3><p>Etanercept, infliximab, or adalimumab are recommended for the
treatment of active and progressive psoriatic arthritis in adults
who have peripheral arthritis with at least 3 tender joints and at
least 3 swollen joints, and who have not responded adequately to at
least 2 standard disease-modifying antirheumatic drugs (used alone
or in combination).<br /></p><p>Etanercept, infliximab, and adalimumab should be discontinued
if there is an inadequate response at 12 weeks.</p></div></div><div id="_200785"><div class="cAZ"><h2>Side-effects</h2> <p class="cAX"><span>Adalimumab</span>, <span>certolizumab pegol</span>, <span>etanercept</span>, golimumab, <span>infliximab</span>, and <span>rituximab</span> have been
associated with infections, sometimes severe, including tuberculosis,
septicaemia, and hepatitis B reactivation. Other side-effects include
nausea, abdominal pain, worsening heart failure, hypersensitivity
reactions, fever, headache, depression, antibody formation (including
lupus erythematosus-like syndrome), pruritus, injection-site reactions,
and blood disorders (including anaemia, leucopenia, thrombocytopenia,
pancytopenia, and aplastic anaemia).</p></div></div><div id="_207446"><p><b>Abatacept</b> prevents the full activation of T-lymphocytes. It is licensed for
moderate to severe active <i>rheumatoid arthritis</i> in
combination with methotrexate, in patients unresponsive to other disease-modifying
antirheumatic drugs (including methotrexate or a tumour necrosis factor
(TNF) inhibitor); see also NICE guidance (<a title="BNF:target-block: NICE guidance cytokine modulators for treatment of rheumatoid arthritis after TNF failure" href="202659.htm#_213716">August 2010</a>) and
(<a title="BNF:target-block: Abatacept NICE guidance rheumatoid arthritis" href="202659.htm#_218730">August 2011</a>).
It is also licensed for the treatment of moderate to severe active <i>polyarticular juvenile idiopathic arthritis</i> (in combination
with methotrexate) in children who have not responded adequately to
other disease-modifying antirheumatic drugs (including at least one
tumour necrosis factor (TNF) inhibitor). Abatacept is not recommended
for use in combination with TNF inhibitors.</p></div><p>The <a title="BNF:target-block: NICE and Scottish Medicines Consortium" href="29404.htm#_200790"><i>Scottish Medicines
Consortium</i></a>  has advised (October 2011) that abatacept (<span class="cZ">Orencia</span>®) is accepted for restricted use within NHS Scotland for adults
with severe active rheumatoid arthritis, in line with NICE guidance <a title="BNF:target-block: NICE guidance cytokine modulators for treatment of rheumatoid arthritis after TNF failure" href="202659.htm#_213716"><i>Adalimumab, etanercept,
infliximab, rituximab, and abatacept for the treatment of rheumatoid
arthritis after the failure of a TNF inhibitor</i></a> (August
2010). It is also accepted for the treatment of moderate to severe
active polyarticular juvenile idiopathic arthritis in accordance with
the licensed indications; its use is restricted to specialist rheumatology
services.</p><div id="_218730"><div class="cN"><h2 class="cBR">NICE guidance</h2><h3 class="cBP">Abatacept for the treatment of rheumatoid arthritis
after the failure of conventional disease-modifying antirheumatic
drugs (August 2011)</h3><p>Abatacept, in combination with methotrexate, is <b>not</b> recommended for the treatment of moderate to severe active rheumatoid
arthritis in adults who have had an inadequate response to one or
more conventional disease-modifying antirheumatic drugs, including
methotrexate. Patients who are already receiving abatacept for this
indication should continue treatment until they and their specialist
consider it appropriate to stop.</p></div></div><div id="_208120"><p><b><span>Anakinra</span></b> inhibits the activity of interleukin-1. <span>Anakinra</span> (in combination with methotrexate) is licensed
for the treatment of <i>rheumatoid arthritis</i> which has
not responded to <span>methotrexate</span> alone; it is not,
however, recommended for routine management of <i>rheumatoid
arthritis</i>, see NICE guidance below. </p><p>The <a title="BNF:target-block: NICE and Scottish Medicines Consortium" href="29404.htm#_200790"><i>Scottish Medicines
Consortium</i></a> has advised (July 2002) that anakinra is <b>not</b> recommended
for the treatment of rheumatoid arthritis within NHS Scotland.</p></div><div class="cN"><h2 class="cBR">NICE guidance</h2><h3 class="cBP"><span>Anakinra</span> for the treatment of
rheumatoid arthritis (February 2009)</h3><p><span>Anakinra</span> is <b>not</b> recommended
for the treatment of rheumatoid arthritis except when used in a controlled
long-term clinical study. Patients who are already receiving <span>anakinra</span> for rheumatoid arthritis should continue treatment
until they and their specialist consider it appropriate to stop.</p></div><div id="_218791"><p><b>Belimumab</b> inhibits
the activity of B-lymphocyte stimulator. Belimumab is licensed as
adjunctive therapy in patients with active, autoantibody-positive
systemic lupus erythematosus with a high degree of disease activity
despite standard therapy. Infusion-related side-effects are reported
commonly with belimumab and occur predominantly during the first 2
infusions. Premedication with an antihistamine, with or without an
antipyretic, may be considered.</p></div><div id="_204106"><p><b>Tocilizumab</b> antagonises
the actions of interleukin-6. Tocilizumab is licensed for use in patients
with moderate to severe active <i>rheumatoid arthritis</i> when response to at least one disease-modifying antirheumatic drug
or tumour necrosis factor inhibitor has been inadequate, or in those
who are intolerant of these drugs. Tocilizumab can be used in combination
with methotrexate, or as monotherapy if methotrexate is not tolerated
or is contra-indicated (see also NICE guidance below).</p></div><div id="_213717"><div class="cN"><h2 class="cBR">NICE guidance</h2><h3 class="cBP">Tocilizumab for the treatment of rheumatoid arthritis
(August 2010)</h3><p>Tocilizumab, in combination with methotrexate, is recommended
for the treatment of moderate to severe active rheumatoid arthritis
in patients who have had an inadequate response to 1 or more tumour
necrosis factor alpha inhibitors <b>and</b>: </p><ul class="cBF"><li><p class="cQ">whose rheumatoid arthritis has responded inadequately
to rituximab <i>or</i></p></li><li><p class="cQ">in whom rituximab is contra-indicated or not tolerated.</p></li></ul></div></div></div></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_130136"><a href="130136.htm" title="ABATACEPT">ABATACEPT</a></li><li id="_128230"><a href="128230.htm" title="ADALIMUMAB">ADALIMUMAB</a></li><li id="_128232"><a href="128232.htm" title="ANAKINRA">ANAKINRA</a></li><li id="_217729"><a href="217729.htm" title="BELIMUMAB">BELIMUMAB</a></li><li id="_204103"><a href="204103.htm" title="CERTOLIZUMAB PEGOL">CERTOLIZUMAB PEGOL</a></li><li id="_128236"><a href="128236.htm" title="ETANERCEPT">ETANERCEPT</a></li><li id="_212247"><a href="212247.htm" title="GOLIMUMAB">GOLIMUMAB</a></li><li id="_128234"><a href="128234.htm" title="INFLIXIMAB">INFLIXIMAB</a></li><li id="_129937"><a href="129937.htm" title="RITUXIMAB">RITUXIMAB</a></li><li id="_203908"><a href="203908.htm" title="TOCILIZUMAB">TOCILIZUMAB</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="5305.htm">Previous: METHOTREXATE</a> | <a class="top" href="202659.htm#">Top</a> | <a accesskey="]" href="130136.htm">Next: ABATACEPT</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>